

TPP
Alberta
TRACKED PRESCRIPTION PROGRAM



2025-26
**Annual
Report**

Using data to optimize
safe patient care.



Table of Contents

- 03** About TPP Alberta
- 04** TPP Alberta Partner Organizations
- 05** 2025–26 Highlights
- 17** 2025–26 Statistics
- 31** 2025–26 Financials
- 34** Appendices
- 44** Online resources

About TPP Alberta

Alberta's Tracked Prescription Program (TPP Alberta) has monitored the use of prescription medication prone to misuse in the province since 1986.

Our mission

TPP Alberta collects data and provides useful reporting to clinicians, member organizations and stakeholders to:

- Promote appropriate use and stewardship of TPP-targeted medications.
- Optimize safe prescribing and patient care.
- Reduce public health and social impacts associated with the use, misuse, and non-medical use of monitored medications.
- Contribute to the health of the public.

Our vision

To use data to optimize patient care and the health of the public.



TPP Alberta Partner Organizations

Administered by the College of Physicians & Surgeons of Alberta (CPSA),
TPP Alberta is a partnership between the following provincial healthcare organizations:





2025-26

Highlights

In 2026, TPP Alberta proudly marks 40 years of advancing safe prescribing and strengthening public protection across Alberta.

Our history

Since 1986, TPP Alberta has grown from a paper-based tracked prescription model into a modern, data-informed system that supports prescribers, informs decision-making, and enhances patient safety.

Forty years on, TPP Alberta stands as a trusted, proactive program grounded in experience, strengthened by partnership, and committed to innovation. This innovation includes the development of the TPP Atlas, enhancing transparency and insight through accessible, data-driven reporting. We have maintained our leadership in addressing complex challenges, including the opioid crisis and antimicrobial stewardship.

As we reflect on our progress, we also look ahead with confidence, continuing to evolve to meet the needs of Albertans and the healthcare system.

23,000+

registered TPP Alberta prescribers since 1986

6,000,000+


TPP Alberta prescriptions ordered since 1986

40 years of...

sustained commitment to public protection and responsible prescribing

TPP Alberta milestones

Over four decades, TPP Alberta has adapted to a changing healthcare landscape, responding to emerging risks, evolving evidence, and increasing system complexity.




Celebrating 40 years of strong collaboration with regulators, healthcare professionals, and government partners.



Over the past four decades, TPP Alberta has evolved alongside the health system—modernizing how monitored medications are tracked and how information is shared—while keeping its focus on patient safety and public protection.

Its progress reflects sustained collaboration among regulators, prescribers, pharmacists, and health system partners, and positions the program to continue strengthening stewardship, supporting evidence-informed prescribing, and responding to emerging risks in the years ahead. The College of Registered Nurses of Alberta is proud to be part of this important initiative.

Marcie Smigorowsky NP, PhD, CCN(C)
Director, College of Registered Nurses of Alberta



In my seven years on the TPP Alberta Steering Committee, I've seen firsthand the program's significant impact on supporting safe medication practices across the province.

I am proud to have contributed to initiatives that continue to evolve to meet the changing needs of patients, prescribers, and the health system. The true strength of TPP Alberta lies in the collaborative partnership of the diverse organizations and individuals who guide its work. As we mark the program's 40th anniversary, I am honoured to step into the role of Chair and help carry forward this collective effort to enable system-level change and advance responsible medication practices across Alberta.

Monty Stanowich
Legislation and Policy Manager, Alberta College of Pharmacy



TPP Alberta is an inherently collaborative program, involving a network of partners—including physicians, pharmacists, regulatory colleges, government and other health system partners—who contribute to governance, data sharing and system-level improvements.

This multi-partner model strengthens accountability and enables coordinated action to optimize prescribing and, ultimately, to support a safer, more integrated healthcare system for Albertans. Together, we ensure secure prescribing processes, oversight of prescribing practices and the provision of analytics and feedback to clinicians.

Ed Jess
Chief Innovation Officer, College of Physicians & Surgeons of Alberta (CPSA)

Tracked Prescription Program (TPP Alberta)

In 2024–25, TPP Alberta strengthened governance, modernized operations, and enhanced reporting to support safe and appropriate prescribing across the province.

A key milestone was the expansion of the TPP Steering Committee to include Alberta’s newly established health agencies, including Acute Care Alberta, Primary Care Alberta, Assisted Living Alberta, and Recovery Alberta. This ensures prescription monitoring oversight remains aligned with Alberta’s evolving health system structure.

The TPP Alberta Interactive Atlas was updated with new prescribing and dispensing data, including the addition of five-year stimulant prescribing trends. The TPP Atlas continues to provide accessible, aggregated insights across geography, age, sex, prescriber type, and medication class, supporting transparency and informed stewardship.

Data quality initiatives progressed through focused collaboration with system partners to address prescriber attribution gaps and medication misclassification within Pharmaceutical Information Network (PIN) data. In parallel, development of a new TPP application is underway to improve workflow efficiency, forgery tracking, and data reliability, with a longer-term shift toward more timely prescribing surveillance.

Together, these initiatives reinforce TPP Alberta’s commitment to proactive monitoring, system collaboration, and responsible modernization in support of public health.

Enhancements to the online interactive TPP Atlas

The TPP Atlas is a dynamic, publicly available online resource that provides detailed analyses of prescription drug utilization in Alberta. Designed to enhance transparency and inform decision-making, the Atlas offers valuable insights into the use of medications that are more susceptible to misuse.


Using primarily community pharmacy dispensing data from the Alberta Netcare Pharmaceutical Information Network (PIN), the Atlas presents dispensing trends and patterns for TPP-monitored medications. The platform currently includes five years of data and covers multiple medication classes, including opioids, benzodiazepines/Z-drugs, antibiotics, and, as of 2025, stimulants.

In 2025, several enhancements were introduced to further strengthen usability and engagement. These included the addition of stimulant data, the launch of a comprehensive “How-To” resource to guide users through Atlas functionality, updated clinical resource links to support interpretation and responsible prescribing, and the introduction of an “Ask Us” page to facilitate feedback and respond to questions about the TPP Atlas.

Through ongoing enhancements and expanded functionality, the TPP Atlas continues to advance transparency, data accessibility, and evidence-informed prescribing across Alberta.

TPP Atlas views

The most accessed page was the opioid regional detail which depicts opioid dispense by Pharmacy Local Aggregated Geography (PhLAG) region.




Total Views
12.50K

Views in Time Period
7723

Total Users
827

Users in Time Period
613

Views by Date



Modernizing TPP Alberta: New application development

TPP Alberta is currently developing a new internal application designed to enhance operational efficiency and strengthen data management processes. This modernization initiative reflects a continued commitment to improving system functionality and supporting the evolving needs of the TPP Alberta team.

The new application will introduce enhanced features to streamline data entry, improve accuracy, and reduce manual processes. By modernizing workflows and optimizing system usability, the platform will support more efficient case management and reporting, enabling the team to focus on higher-value analytical and oversight activities.

Once implemented, the application will provide a more intuitive and reliable interface for TPP Alberta team members, strengthening data integrity and supporting the program's ongoing commitment to excellence, responsiveness, and continuous improvement.



Modernizing TPP Alberta: Process automation assessment

In 2025, the College of Physicians & Surgeons of Alberta (CPSA) advanced modernization efforts within TPP Alberta through a comprehensive Process Automation Assessment. The assessment identified significant opportunities to streamline critical workflows and improve operational efficiency through targeted automation.

The review examined high-impact processes, including registration, pad ordering, prescription handling, and shipping. It found that manual data entry, repetitive validations, and fragmented communications were key sources of inefficiency and areas where there may be an increased risk of inconsistency.

The assessment outlined a modernization roadmap to improve workflow integration, enable real-time validation processes, enhance reporting capabilities, and automate routine administrative tasks while maintaining appropriate quality oversight. These enhancements are designed to reduce administrative burden, improve data accuracy, and strengthen compliance.

A return-on-investment analysis demonstrated meaningful projected time and cost savings, supported by scalable infrastructure to accommodate future growth. This work provides CPSA with a clear and strategic path forward, positioning TPP Alberta to enhance service delivery, improve data integrity, and strengthen stakeholder confidence while aligning with privacy, security, and audit requirements.

Updates to the TPP Type 2 Medication List

In January 2026, lincomycin and spiramycin were removed from the TPP Alberta Type 2 medications list following their post-market cancellation. During the same period, oritavancin was added to the Type 2 medications list as a newly authorized medication in the Canadian market.

TPP Website Revitalization in 2025/2026

A revamp of the TPP Alberta website began in 2025 and is scheduled to launch in 2026/27 to enhance user accessibility and engagement. The goal is to redesign the layout of the website to improve user experience.



Physician Prescribing Practices (PPP) Program: Antibiotic Stewardship

In 2024–25, CPSA’s Physician Prescribing Practices (PPP) Program undertook a comprehensive redesign of the antibiotic page within the quarterly MD Snapshot-Prescribing report, an online audit and feedback tool. Physicians prescribe approximately two-thirds of antibiotics dispensed to patients in Alberta, and the MD Snapshot-Prescribing report plays an important role in supporting antimicrobial stewardship.

Through Alberta’s participation in the Canadian Antibiotic Prescribing Feedback Initiative (CANBuild-AMR), CPSA collaborated with national audit and feedback experts and partners, including Choosing Wisely Alberta. Insights from this initiative informed a re-envisioning of the MD Snapshot-Prescribing report’s antibiotic content to improve clarity, structure, and clinical relevance. The redesigned reporting page, launched in fall 2025, enhances interpretability and supports meaningful physician reflection on prescribing patterns. This work was highlighted at the Antimicrobial Resistance Symposium in Toronto in November 2025, where Alberta’s approach to prescribing feedback was shared nationally.

By strengthening the design and usability of physician-facing prescribing reports, PPP continues to advance evidence-informed antibiotic stewardship and contribute to broader efforts to combat antimicrobial resistance.

MD Snapshot–Prescribing reporting

CPSA’s Physician Prescribing Practices (PPP) Program continues to generate individualized MD Snapshot-Prescribing reports for physicians in the province on a quarterly basis to increase prescribing awareness and identify opportunities to optimize prescribing and ultimately patient care. Data from these reports can be used to support individual physicians in self-directed quality improvement activities.

Physicians who prescribed an antibiotic, opioid and/or a sedative (Benzodiazepines or Z-drugs)

	2025	2024
Q1	11,348	10,845
Q2	11,284	10,849
Q3	11,734	11,283
Q4	11,903	11,353

2025-26


Statistics

TPP Alberta employs a dedicated data entry team to enter TPP prescription information not captured in the Alberta Health Pharmaceutical Information Network (PIN) system (e.g., office use, veterinary prescriptions, compound prescriptions).

- Prescriptions entered in 2025: 38,079
- Corrections completed in 2025: 35
- PIN data error inquiries in 2025: 20
- Total pads ordered in 2025: 9,934
- TPP pad reorder forms processed in 2025: 3,369
- Medication list webpage views in 2025: 24,966
- New TPP registrants in 2025: 926

The following figures and tables illustrate medication prescribing trends throughout the province.


Five years of dispenses by medication class (2021-2025)



	2021	2022	2023	2024	2025
Antibiotics	2,523,716	3,088,295	3,417,470	3,602,621	3,754,765
Benzodiazepine and Z-Drugs	2,140,321	2,055,596	2,008,241	1,983,068	1,950,286
Gabapentinoids	1,138,258	1,187,181	1,280,194	1,404,604	1,497,627
Opioids	3,354,935	3,289,102	3,151,982	3,134,977	3,216,161
Stimulants	977,947	1,176,433	1,393,943	1,598,658	1,799,356

Antibiotics Benzodiazepine and Z-Drugs Gabapentinoids Opioids Stimulants

Five-year rates per 1,000 dispenses by medication class (2021-2025)




	2021	2022	2023	2024	2025
Antibiotics	569.5	684.4	728.9	733.9	746.6
Benzodiazepine and Z-Drugs	483.0	455.5	428.3	404.0	387.8
Gabapentinoids	256.9	263.1	273.0	286.1	297.8
Opioids	757.1	728.8	672.3	638.6	639.5
Stimulants	220.7	260.7	297.3	325.7	357.8


Antibiotics Benzodiazepine and Z-Drugs Gabapentinoids Opioids Stimulants

Note: Population estimates derived from the Interactive Health Data Application included in Appendix A

2025 dispenses by prescriber type




Antibiotic dispenses (2021-2025)




Note: Counts included in Appendix B

Dual Orexin Receptor Antagonist dispenses (2021-2025)




Note: Daridorexant marketed in Canada in 2023, Lemborexant marketed in Canada in 2020

Opioid dispenses (2021-2025)




Note: Counts included in Appendix C


Stimulant dispenses (2021-2025)



Gabapentinoids dispenses (2021-2025)




Benzodiazapine and Z-Drug dispenses (2021-2025)



Note: Counts included in Appendix D


Veterinary dispenses (2021-2025)




Note: Counts included in Appendix E

Five-year trend of greater than 90 Oral Morphine Equivalents (OME) (2021-2025)

Rate of patients per 1,000 prescribed 90+ OME per day



Patients prescribed an average of 90+ OME per day




Note: Counts included in Appendix F

Five-year trend of patients 65+ prescribed a Benzodiazepine or Z-Drug (2021-2025)

Rate per 1,000 patients




Number of patients




Note: Counts included in Appendix G

Five-year trend of opioid agonist therapy dispenses by modality

Buprenorphine dispenses



Methadone and morphine dispenses




Note: Counts included in Appendix H

2025-26

Financials

TPP Alberta Grant Report | Financial Summary


		Interim Report #3	GAMS Grant ID: 017357
College of Physicians & Surgeons of Alberta		UNAUDITED FINANCIAL REPORTING FOR GRANTS MULTI-YEAR AGREEMENT YEAR 3 OF 3	
Description of Grant: Support the TPP Alberta program, established to monitor the use of certain drugs prone to misuse and abuse.			
Reporting Period for Agreement:	01-Apr-25 to 31-Dec-25	Date:	08-May-26
Financial Reporting for the Period:	01-Apr-23 to 31-Mar-26		

	Current Fiscal Year (April 1, 2025 - March 31, 2026)			Agreement-to-Date Period (April 1, 2023 - March 31, 2026) - FULL TERM		
	Budget	Forecast* Year 3	Variance	Budget	Agreement-To-Date Forecast* All Years	Variance
Revenue						
Contribution from Alberta Health	756,815.00	756,815.00	-	2,064,223.25	2,014,223.00	(50,000.25)
Contribution from Alberta Health - outstanding payment	100,000.00	85,730.25	(14,269.75)	100,000.00	85,730.25	(14,269.75)
Alberta Health Grant (surplus Mar '23)	-	-	-	259,562.75	259,562.75	-
CPSA contribution	196,769.00	214,234.00	17,465.00	576,050.00	602,562.00	26,512.00
Investment income	-	5,061.50	5,061.50	-	10,867.29	10,867.29
Partner contributions	148,598.00	137,400.00	(11,198.00)	430,268.00	412,200.00	(18,068.00)
Total Revenue	1,202,182.00	1,199,240.75	(2,941.25)	3,430,104.00	3,385,145.29	(44,958.71)
Expense						
General Program Expenditures						
Consulting	322,416.00	424,905.53	102,489.53	924,945.00	1,088,453.77	163,508.77
Legal	495.00	1,545.51	1,050.51	1,472.00	2,305.51	833.51
Computer Software & Supplies	-	-	-	-	181.10	181.10
Courier	483.00	498.40	15.40	1,372.00	5,960.62	4,588.62
Photocopying	750.00	847.81	97.81	2,217.00	2,480.80	263.80
Postage	1,137.00	-	(1,137.00)	3,262.00	182.76	(3,079.24)
Printing, Stat & Supplies	19,611.00	2,661.11	(16,949.89)	56,877.00	5,064.45	(51,812.55)
Sundry	255.00	113.49	(141.51)	745.00	145.37	(599.63)
Telephone & Fax	2,442.00	-	(2,442.00)	7,051.00	1,334.51	(5,716.49)
Web Site/Internet	327.00	483.73	156.73	945.00	1,253.37	308.37
Office Supplies	25,005.00	4,604.54	(20,400.46)	72,469.00	16,602.98	(55,866.02)
Occupancy Costs	31,701.00	31,080.00	(621.00)	91,376.00	90,280.00	(1,096.00)
Operating Costs	64,722.00	90,185.00	25,463.00	185,289.00	230,598.00	45,309.00
Printing - Special	359,568.00	221,317.82	(138,250.18)	1,042,791.00	874,577.28	(168,213.72)
Sub-total	803,907.00	773,638.40	(30,268.60)	2,318,342.00	2,302,817.54	(15,524.46)

TPP Alberta Grant Report | Financial Summary

	Current Fiscal Year (April 1, 2025 - March 31, 2026)			Agreement-to-Date Period (April 1, 2023 - March 31, 2026) - FULL TERM		
	Forecast*			Agreement-To-Date Forecast*		
	Budget	Forecast* Year 3	Variance	Budget	Forecast* All Years	Variance
Staffing Costs						
Salaries & Benefits	393,187.00	424,814.63	31,627.63	1,097,566.00	1,073,695.77	(23,870.23)
Professional Development	5,088.00	3,287.90	(1,800.10)	14,196.00	8,538.90	(5,657.10)
Sub-total	398,275.00	428,102.53	29,827.53	1,111,762.00	1,082,234.67	(29,527.33)
Committee Expenditures						
Travel	-	-	-	-	43.60	43.60
Meals	-	-	-	-	49.48	49.48
Sub-total	-	-	-	-	93.08	93.08
Total Expenses	1,202,182.00	1,201,740.93	(441.07)	3,430,104.00	3,385,145.29	(44,958.71)
Surplus < Deficit >	-	(2,500.18)	(2,500.18)	-	-	-

* As per AH request, forecast includes actuals for the period up to March 31, 2026

Unexpended Funding		Opening Balance: Prior Year's Cumulative Unspent Retention		2,500.18
<input type="checkbox"/> Attached Request(s) for		Add (Subtract) Current Surplus/ (Deficit):		(2,500.18)
Retention of Unexpended Funding Form (FINAL YEAR ONLY)		Less: Approved Request(s) for Retention of Unexpended Funding (FINAL YEAR ONLY)		-
		Closing Balance: Cumulative Unspent Retention <Deficit>		0.00
		31-Mar-26		
Finance Contact:		Program Contact:		
Julia Rudolf Name	(780) 401-0982 Phone #	Ed Jess Name	780-969-4946 Phone #	
Finance Approval:				
Tracy Simons Name	CFO / 780-969-4983 Position / Phone #	08-May-26 Date	 Digitally signed by Tracy Simons Date: 2026.05.08 15:36:39 -06'00' Signature	



2025-26

Appendices

Appendix A | Annual Alberta Population Estimates from the Interactive Health Data Application (IHDA)

Geography	Year	Sex	Age	Population
Alberta	2021	BOTH	ALL	4,431,540
Alberta	2022	BOTH	ALL	4,512,741
Alberta	2023	BOTH	ALL	4,688,589
Alberta	2024	BOTH	ALL	4,909,041
Alberta	2025	BOTH	ALL	5,029,358

Note: Population estimates were derived from the [Interactive Health Data Application](#) for the table, 'Five-year rates per 1,000 dispenses by medication class'

Appendix B | Antibiotic dispenses (2021-2025)

	2021	2022	2023	2024	2025
AMOXICILLIN	427,261	647,148	703,676	737,609	774,125
AZITHROMYCIN	116,157	241,795	282,098	296,949	328,481
AMOX-CLAV	147,570	210,926	252,537	269,811	297,166
CEPHALEXIN	218,757	229,452	264,257	276,872	285,535
DOXYCYCLINE	113,936	141,913	163,769	195,404	227,662
CIPROFLOXACIN	207,512	223,918	220,151	213,039	208,448
NITROFURANTOI	144,195	149,075	171,017	171,913	192,788
METRONIDAZOLE	121,771	122,048	128,715	141,670	155,091
TOBRAMYCIN	91,629	126,995	152,810	172,518	148,064
FUSIDIC ACID	104,984	112,301	128,726	132,781	138,032
CLINDAMYCIN	140,700	130,592	125,114	126,419	128,887
CEFIXIME	74,105	85,571	102,135	117,191	122,105
MUPIROCIN	75,881	81,271	89,611	102,254	113,207
SMX-TMP	96,068	93,575	102,253	110,424	104,722
MOXIFLOXACIN	66,401	69,886	81,446	80,527	74,780

Note: This table includes the top 15 dispensed antibiotics in 2025. The 15 account for 87.9% of all antibiotic dispenses in 2025. For additional data, please refer to the [TPP Alberta Atlas](#).

Appendix C | Opioid dispenses (2021-2025)

	2,021	2,022	2,023	2,024	2,025
CODEINE	895,544	876,011	844,144	829,673	849,976
METHADONE	668,417	638,014	567,718	527,537	528,680
BUPRENORPHINE	411,498	393,540	383,239	390,028	394,903
HYDROMORPHONE	314,024	326,279	324,861	346,943	364,822
OXYCODONE	418,367	403,866	379,282	364,043	362,189
MORPHINE	289,554	300,845	294,654	314,435	344,902
TRAMADOL	312,380	308,380	318,373	325,111	335,219
FENTANYL	34,792	32,675	30,371	28,412	26,783
TAPENTADOL	5,053	4,691	4,223	3,413	3,340
BUTALBITAL	2,936	2,652	2,559	2,310	2,189

Note: This table includes the top 10 dispensed opioids in 2025. The 10 account for >99.9% of all antibiotic dispenses in 2025. For additional data, please refer to the [TPP Alberta Atlas](#).

Appendix D | Benzodiazepine and Z-drug dispenses (2021-2025)

	2021	2022	2023	2024	2025
ZOPICLONE	857,695	816,693	798,831	792,730	774,473
LORAZEPAM	453,633	440,415	433,898	429,932	434,774
CLONAZEPAM	400,864	390,902	378,902	369,769	354,856
DIAZEPAM	94,594	86,360	87,149	87,000	87,747
TEMAZEPAM	112,801	104,857	94,851	88,484	83,921
ZOLPIDEM	78,825	77,803	79,189	80,557	81,428
CLOBAZAM	38,755	40,040	44,027	48,010	50,140
ALPRAZOLAM	40,067	37,939	34,626	33,087	33,553
BROMAZEPAM	21,702	19,374	18,050	17,825	15,469
NITRAZEPAM	15,605	14,870	13,358	12,694	11,261
TRIAZOLAM	6,291	5,927	6,058	5,863	6,192
OXAZEPAM	8,208	7,559	6,893	6,117	5,607
MIDAZOLAM	3,122	3,727	3,864	4,320	4,743
ESZOPICLONE	2,761	3,998	4,164	3,773	3,513
CHLORDIAZEPOXID	3,630	3,697	3,124	1,695	1,506

Note: This table includes the top 15 dispensed benzodiazepine and z-drugs in 2025. The 15 account for >99.9% of all antibiotic dispenses in 2025. For additional data, please refer to the [TPP Alberta Atlas](#).

Appendix E | Veterinary dispenses (2021-2025)

	ALPRAZOLAM	BUPRENORPHINE	BUTORPHANOL	CODEINE	DIAZEPAM	HYDROCODONE	MIDAZOLAM	OXYCODONE	PHENOBARBITAL	TRAMADOL	Total
2021-Q1	224	1,532	113	531	177	1,347	19	137	3,395	1,868	9,343
2021-Q2	253	1,540	124	545	185	1,325	19	184	3,439	1,659	9,273
2021-Q3	260	1,418	90	495	171	1,520	24	169	3,350	1,286	8,783
2021-Q4	195	1,648	108	484	167	1,429	25	184	3,597	1,325	9,162
2022-Q1	153	1,683	92	495	206	1,248	10	199	3,617	1,157	8,860
2022-Q2	244	1,625	82	539	202	1,352	33	252	3,571	1,135	9,035
2022-Q3	223	1,512	77	594	124	1,359	36	214	3,519	965	8,623
2022-Q4	203	1,488	36	472	141	1,405	43	260	3,647	992	8,687
2023-Q1	181	1,452	27	494	168	1,378	45	267	3,665	845	8,522
2023-Q2	234	1,476	24	541	171	1,154	45	277	3,698	697	8,317
2023-Q3	241	1,563	39	531	175	1,485	54	265	3,736	724	8,813
2023-Q4	263	1,631	27	658	178	1,587	63	257	3,708	744	9,116

Note: These medications account for 98.7% of TPP Alberta monitored dispenses in 2025. Medications are recorded once they are sent into TPP Alberta and entered into our monitoring system. We experience approximately a six-month lag for final results which explains the dip for 2025 Q3 and Q4.

Appendix E | Veterinary dispenses contd. (2021-2025)

	ALPRAZOLAM	BUPRENORPHINE	BUTORPHANOL	CODEINE	DIAZEPAM	HYDROCODONE	MIDAZOLAM	OXYCODONE	PHENOBARBITAL	TRAMADOL	Total
2024-Q2	304	1,527	27	676	193	1,304	73	231	3,947	679	8,961
2024-Q3	294	1,487	19	732	175	1,278	70	234	3,934	596	8,819
2024-Q4	216	1,536	28	742	217	1,386	98	262	3,990	528	9,003
2025-Q1	209	1,684	23	677	208	1,278	87	276	3,884	528	8,854
2025-Q2	232	1,654	22	712	200	1,203	101	336	3,861	508	8,829
2025-Q3	215	1,495	25	625	160	1,170	101	266	3,625	434	8,116
2025-Q4	123	1,221	21	555	115	1,087	94	242	3,049	347	6,854
Total	4,473	30,771	1,040	11,777	3,534	26,656	1,122	4,757	73,089	17,800	175,019

Note: These medications account for 98.7% of TPP Alberta monitored dispenses in 2025. Medications are recorded once they are sent into TPP Alberta and entered into our monitoring system. We experience approximately a six-month lag for final results which explains the dip for 2025 Q3 and Q4.

Year Quarter	90+ OME/Day Patients/1000
2021-Q1	2.3
2021-Q2	2.35
2021-Q3	2.29
2021-Q4	2.3
2022-Q1	2.18
2022-Q2	2.16
2022-Q3	2.13
2022-Q4	2.13
2023-Q1	2
2023-Q2	2.01
2023-Q3	1.96
2023-Q4	1.93
2024-Q1	1.8
2024-Q2	1.83
2024-Q3	1.8
2024-Q4	1.83
2025-Q1	1.74
2025-Q2	1.77
2025-Q3	1.74
2025-Q4	1.77

Year Quarter	90+ OME/Day Patients
2021-Q1	10,216
2021-Q2	10,436
2021-Q3	10,182
2021-Q4	10,206
2022-Q1	9,896
2022-Q2	9,812
2022-Q3	9,690
2022-Q4	9,678
2023-Q1	9,373
2023-Q2	9,452
2023-Q3	9,203
2023-Q4	9,041
2024-Q1	8,806
2024-Q2	8,960
2024-Q3	8,803
2024-Q4	8,926
2025-Q1	8,526
2025-Q2	8,653
2025-Q3	8,522
2025-Q4	8,636

Appendix F | Five-year trend of greater than 90 Oral Morphine Equivalents (OME) (2021-2025)

Year Quarter	Patients 65+ per 1,000
2021-Q1	258.6
2021-Q2	259
2021-Q3	259
2021-Q4	257.3
2022-Q1	249.2
2022-Q2	246.2
2022-Q3	241.1
2022-Q4	244
2023-Q1	240.6
2023-Q2	241.1
2023-Q3	234.7
2023-Q4	236.7
2024-Q1	236.1
2024-Q2	235.8
2024-Q3	233
2024-Q4	232.2
2025-Q1	234.4
2025-Q2	234.7
2025-Q3	232
2025-Q4	230

Year Quarter	Patients 65+
2021-Q1	165,249
2021-Q2	165,548
2021-Q3	165,537
2021-Q4	164,471
2022-Q1	167,535
2022-Q2	165,548
2022-Q3	162,100
2022-Q4	164,044
2023-Q1	170,059
2023-Q2	170,444
2023-Q3	165,921
2023-Q4	167,356
2024-Q1	174,868
2024-Q2	174,660
2024-Q3	172,559
2024-Q4	172,016
2025-Q1	173,634
2025-Q2	173,835
2025-Q3	171,874
2025-Q4	170,328

Appendix G | Five-year trend of patients 65+ prescribed a Benzodiazepine or Z-Drug (2021-2025)

Year Quarter	Oral Disperses	Subcutaneous Disperses	SubLingual Disperses
2021-Q1	3	263	93,443
2021-Q2	244	355	93,565
2021-Q3	240	426	96,930
2021-Q4	482	662	105,572
2022-Q1	485	1,391	101,393
2022-Q2	502	1,922	92,319
2022-Q3	724	2,191	86,389
2022-Q4	1,790	2,364	83,673
2023-Q1	1,834	2,669	83,561
2023-Q2	1,587	3,131	86,489
2023-Q3	1,942	3,562	86,600
2023-Q4	1,800	3,987	87,764
2024-Q1	2,415	4,316	87,298
2024-Q2	2,871	4,587	83,613
2024-Q3	4,203	4,671	83,319
2024-Q4	6,968	4,620	82,636
2025-Q1	8,765	4,779	80,098
2025-Q2	10,057	4,938	79,328
2025-Q3	11,915	4,955	77,453
2025-Q4	14,760	5,379	75,361

Year Quarter	Oral Morphine	Oral Methadone
2021-Q1	41,131	154,573
2021-Q2	41,806	160,925
2021-Q3	36,750	158,852
2021-Q4	43,064	159,802
2022-Q1	46,118	156,402
2022-Q2	49,444	152,229
2022-Q3	46,972	149,325
2022-Q4	45,481	150,007
2023-Q1	45,795	142,278
2023-Q2	48,326	135,802
2023-Q3	49,886	131,199
2023-Q4	50,710	128,097
2024-Q1	54,404	128,943
2024-Q2	54,238	126,185
2024-Q3	54,151	122,129
2024-Q4	56,393	121,437
2025-Q1	58,781	123,507
2025-Q2	62,974	126,697
2025-Q3	68,442	125,507
2025-Q4	68,931	124,204

Appendix H | Five-year trend of Opioid Agonist Therapy dispenses by modality (2021-2025)



Online resources

Visit the TPP Alberta Atlas here

Find TPP Alberta resources here

Visit the TPP Alberta website here

View the TPP Alberta Medication List here

Visit the TPP Alberta Program Guide here

Questions? Please contact TPP Alberta at tpp.info@cpsa.ab.ca.